Oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment offer new hope to both pre-and post-liver transplant (LT) patients. However, whether to treat HCV patients before vs after LT is not clear because treatment can improve liver function but could reduce the chance of receiving an LT while on the waiting list. Our objective was to evaluate the cost effectiveness of pre-LT vs post-LT HCV treatment with oral DAAs in decompensated cirrhotic patients on the LT waiting list.
1 Approximately 15% to 20% of patients with HCV-related cirrhosis advance to decompensated cirrhosis or hepatocellular carcinoma within 10 years. 1 For these patients, mortality rates increase to approximately 15% to 20% per year, and liver transplant becomes the only viable option for long-term survival.
Despite the clear benefits of DAAs, the optimal timing of HCV treatment, pre-LT vs post-LT, is not clear. 2, 5 There is a trade-off-pre-LT HCV treatment can improve patients' Model for End-stage Liver Disease (MELD) score and reduce mortality while on the waiting list; however, it also may delay LT by decreasing patients' priority on the waiting list. This situation has been termed "MELD limbo" or "MELD purgatory." 5 Furthermore, by eradicating HCV before transplant, some patients no longer would be eligible to receive an HCV-positive liver, which could reduce their chance of getting a transplant further. On the other hand, for some patients, not receiving pre-LT HCV treatment and waiting until LT could result in worsening of the underlying liver condition and increasing mortality while on the waiting list. Such tradeoffs need to be balanced to optimize patient outcomes.
In addition, the decision regarding the optimal time to treat HCV should take into account limited monetary resources. The high price of DAAs has created concerns about their impact on health care budgets, delaying timely treatment for many HCV patients, and has led to a debate about the value and affordability of these drugs. 6 Three recent studies addressed this topic but reached conflicting conclusions: 2 studies concluded that pre-LT HCV treatment always is cost effective, 7, 8 whereas another study concluded that pre-LT HCV treatment is cost effective if patients' MELD score is 25 or less and post-LT treatment is cost effective if their MELD score is higher than 25. 9 Therefore, the objective of our study was to generate evidence for the optimal timing of HCV treatment by determining the cost effectiveness of pre-LT vs post-LT HCV treatment with approved oral DAAs in decompensated cirrhotic patients on the waiting list.
Materials and Methods

Model Overview
We used a validated, individual-level, state-transition model of liver transplant candidates, that simulated a virtual trial comparing long-term outcomes of pre-LT vs post-LT HCV treatment with oral DAAs. 10 The model simulated the lifetime course of patients on the transplant waiting list and after LT (Figure 1) . The model's outcomes were validated using data from the United Network for Organ Sharing (UNOS). In this analysis, we extended that model to evaluate the cost effectiveness of pre-LT vs post-LT HCV treatment. We used a weekly cycle to advance time in the model and simulated 1 million patients to reduce simulation noise.
Baseline Population
We simulated patients with decompensated cirrhosis (without hepatocellular carcinoma) infected with HCV genotypes 1 or 4. The mean age of patients in the model was 50 years and their MELD scores ranged from 10 to 40.
Interventions
For each patient, we simulated 2 scenarios, as follows: scenario 1 consisted of HCV treatment before LT (pre-LT treatment), and scenario 2 consisted of HCV treatment after LT (post-LT treatment). Patients were treated with sofosbuvir and ledipasvir plus ribavirin for up to 12 weeks. The sustained virologic response (SVR) rates of sofosbuvir plus ledipasvir for pre-LT and post-LT were derived from the SOLAR-1 and SOLAR-2 studies. [11] [12] [13] In pre-LT treatment, HCV patients were treated while on the waiting list. If a patient underwent LT after fewer than 6 weeks of antiviral therapy, the treatment was assumed to be incomplete. On the other hand, if patients received at least 6 weeks of antiviral therapy before the transplant, we assumed that the treatment was complete and patients could achieve SVR. Our assumption was based on data from Curry et al 4 that reported that 93% of patients by week 4 of their treatment had undetectable HCV RNA levels, and among those who remained HCV RNA negative for 4 weeks or longer at the time of LT and cessation of antiviral therapy, only 1 of 26 experienced post-LT recurrence of viremia. The SVR rate for pre-LT treatment was 84%, as reported by the SOLAR-1 and SOLAR-2 studies. [11] [12] [13] If patients failed to achieve SVR, they were re-treated 3 months after LT. We selected the 3-month window as a time point that was sufficiently distanced from LT to minimize any perturbations of the immediate post-LT period but sufficiently early before progressive allograft disease could develop. Patients' MELD score was adjusted according to their SVR status after the treatment.
In post-LT treatment, patients were not treated until after the LT. Patients' MELD score could change while on the waiting list. All patients were offered HCV treatment 3 months after LT. The SVR rate for post-LT treatment was 95%, as reported by SOLAR-1 and SOLAR-2 studies. [11] [12] [13] We varied the SVR rates in the sensitivity analysis. For both strategies, patients were treated only once after the transplant.
Disease Progression
While on the waiting list, patients' MELD scores could increase, decrease, or remain the same. Based on their MELD score, patients could undergo LT or die either because of liver-related or all-cause mortality. If patients were treated on the waiting list, we determined patients' SVR status 4 weeks after the treatment ended. If patients achieved SVR, their MELD scores were adjusted based on the reported data (Supplementary Figure 1) ; otherwise, their MELD scores continued to follow the natural course of the disease until they received a transplant. To determine the clinical course of patients, we used a previously published study based on UNOS data to estimate the weekly increase or decrease in MELD score (ie, the natural course of the disease).
14, 15 We also estimated mortality on the waiting list based on the MELD score from the same data source (Supplementary Table 1 ).
Three months after the liver transplant, patients received treatment if they were still viremic. If patients cleared HCV RNA, they moved to the SVR state; otherwise, they progressed from the F0-F2 state (Figure 1) . A patient's graft could fail; in that case the patient would go back to the waiting list and would be eligible for retransplantation.
Liver Transplant
We used a published study to estimate the weekly probability of receiving a LT based on a patient's current MELD score 16 (Supplementary Table 2 ). For patients who were treated for HCV on the waiting list, we accounted for a reduction in the probability of getting an LT because they will no longer be eligible to receive an HCV-positive liver. Specifically, we narrowed the donor pool by 8% (ie, national HCVþ organ rate) and adjusted the probability of getting an LT accordingly. 17 Patients who needed retransplantation went back to the LT waiting list. Because we did not know their MELD score at that time, we assigned the average probability of LT and liver-related mortality to these patients, which were estimated from UNOS data. Specifically, the weekly probability of death and receiving an LT in patients who had graft failure were estimated as 0.020 and 0.0308, respectively (Supplementary Table 3 ).
Costs
Patients in both strategies incurred costs that included cost while on the waiting list, 1-time cost of the transplantation, and the annual cost of post-LT patient management. We used previously published studies to determine the health-state, ie, corresponding to a stage in the natural history of the disease, costs in our model (Supplementary Table 3) . 18, 19 Treatment costs included the wholesale acquisition costs of sofosbuvir, ledipasvir, and ribavirin. 20 All costs were converted to 2016 US dollars using the Consumer Price Index. We conducted a sensitivity analysis on a wide range of costs.
Health-Related Quality of Life
We assigned health-related quality-of-life utilities for each health state in our model, with 0 denoting death and 1 denoting perfect health, and adjusted them for age and sex. We derived European Quality of Life Five Dimension instrument values from published studies and adjusted them to the US population norm (Supplementary Tables 3 and 4) .
21-23
Model Outcomes
For each MELD score, we estimated total costs, life years, quality of life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) for pre-LT vs post-LT HCV treatment. We also projected these outcomes for each of the 11 UNOS regions. Specifically, we adjusted the probability of undergoing LT and mortality on the waiting list for each region using region-specific transplantation and death rates (Supplementary Table 5 ). We also compared regions according to the incremental net monetary benefit of treating patients before LT in that region. All future costs and QALYs were discounted at 3% per year.
Sensitivity Analysis
We performed a 1-way sensitivity analysis on the selected MELD scores when the cost-effectiveness results changed and estimated the impact of model parameters on the ICER. We further conducted a probabilistic sensitivity analysis by simultaneously changing all model parameters for 50,000 first-order and 1000 second-order samples using the recommended statistical distributions to define uncertainty around each model parameter (Supplementary Table 3 ). We then calculated the probability of the cost effectiveness of pre-LT HCV treatment for each MELD score at the commonly accepted willingness-to-pay threshold (ie, $100,000).
Results
Cost-Effectiveness Analysis
QALYs of pre-LT and post-LT treatment varied by patients' MELD scores. For lower MELD scores, QALYs were higher with pre-LT HCV treatment compared with post-LT treatment, implying that pre-LT HCV treatment was more effective. However, for higher MELD scores, the trend was reversed (Table 1) . Patients with a MELD score of 27 or less could benefit from HCV treatment before LT, and patients with MELD scores greater than this threshold would benefit from waiting until after LT for treatment.
When we accounted for costs, we found that pre-LT HCV treatment was cost saving (ie, increased QALYs and decreased costs) in patients with MELD scores of 15 or less, and cost effective (ie, increased QALYs and costs, but one is willing to pay for higher costs) in patients with MELD scores of 16 to 21 at the commonly accepted willingness-to-pay threshold of $100,000 per QALY (Table 1) . However, in patients with MELD scores of 22 to 27, even though pre-LT HCV treatment resulted in higher QALYs, treatment was not cost effective (ICER > $100,000/QALY). If the price of DAAs decreased to less than $51,000 (ie, $4250/wk) and $16,000 (ie, $1333/ wk), pre-LT treatment became cost effective in patients with MELD scores of 22 to 23 and 24 to 25, respectively. However, for MELD scores of 26 to 27, no price reduction could make pre-LT treatment cost effective (Figure 2 ). For patients with a MELD score of 27 or higher, post-LT HCV treatment was more effective as well as cost effective. Furthermore, in patients with a MELD score of 30 or greater, post-LT HCV treatment resulted in cost savings. 
Cost Effectiveness by United Network for Organ Sharing Regions
We also analyzed the results for each UNOS region to account for differences in waiting time for LT. For region 3, region 10, and region 11, which had relatively shorter waiting times for LT, pre-LT treatment was cost effective/ saving in patients with MELD scores of 19 or less (rather than MELD scores of 21). For the other regions, costeffectiveness results remained the same as the national results ( Figure 3) . The price threshold for DAAs below which pre-LT HCV treatment remained cost effective varied between $8600 and $74,000, depending on the MELD score and UNOS region ( Supplementary  Figures 2-12 ). The incremental net monetary benefit or pre-LT treatment was lower for regions that had a shorter time on the waiting list (Supplementary Figure 13) .
Sensitivity Analysis
Because the cost-effectiveness decisions changed at MELD scores of 20, 22, 24, and 26, we conducted a 1-way sensitivity analysis on these MELD scores to estimate the impact of model parameters on the ICER. The 10 most sensitive model parameters for each MELD score are shown by tornado diagrams (Figure 4 ). For MELD scores of 22, 24, and 26, none of the parameters changed the cost effectiveness of pre-LT HCV treatment. For a MELD score of 20, the model was sensitive to the cost of the LT, SVR rate for pre-LT HCV treatment, and quality-of-life of patients on the waiting list and patients who had SVR.
The probabilistic sensitivity analysis at the national level found that pre-LT HCV treatment was cost effective with a high probability (0.7-1.0) in patients with MELD scores of 21 or less, and vice versa ( Figure 5 ). Some variation was observed in the results of UNOS regions 3, 6, 10, and 11 in patients with MELD scores of 20 to 21, for which the probability of cost effectiveness of pre-LT HCV treatment was less than 0.5.
Discussion
Oral DAAs offer new hope for improving long-term outcomes in HCV-infected patients with decompensated cirrhosis. However, the decision to treat HCV pre-LT In addition, such trade-offs need to factor in the cost effectiveness and value of pre-LT vs post-LT HCV treatment. In this study, we simulated a virtual clinical trial to evaluate such trade-offs and found that pre-LT HCV treatment was cost effective/saving in patients with MELD scores of 21 or less. Waiting to treat until after LT was the most cost-effective/saving strategy in patients with higher MELD score. These results may guide clinicians and payers about the optimal timing of HCV treatment in decompensated cirrhotic patients who are liver transplant candidates.
Prior studies have provided conflicting evidence about the cost effectiveness of timing of HCV treatment. [7] [8] [9] Our study supports the results by Njei et al, 9 that found that pre-LT HCV treatment is cost effective in patients with lower MELD scores (MELD score 25) and post-LT treatment is cost effective in patients with higher MELD scores. In contrast, Ahmed et al 7 and Tapper et al   8 concluded that pre-LT HCV treatment was always cost effective in patients on the waiting list. We believe the reason for these conflicting findings is that these studies aggregated all patients with MELD scores of 15 or higher into 1 category and thus failed to identify a threshold above which post-LT HCV treatment could be cost effective. In fact, a previous study showed that pre-LT HCV treatment in patients with a MELD score higher than 27 could harm them by delaying their LT. 10 Our study, because it considered MELD as a continuum, provided more granular results by MELD scores and thus aids patient-level decision making. Furthermore, we also analyzed results for each UNOS region.
Our study had numerous strengths. First, we conducted a comprehensive analysis to determine the optimal time for HCV treatment in terms of cost effectiveness. We used a validated mathematical model that simulated a virtual trial comparing the long-term clinical and cost outcomes in decompensated cirrhotic patients. 10 Second, our study analyzed the cost effectiveness of HCV treatment timing by each MELD score between 10 and 40. Third, we accounted for lower transplant rates if HCV patients were treated on the waiting list; therefore, these patients would not be eligible for HCV-infected donor organs. Fourth, although we used sofosbuvir-based therapy, our analysis was not limited to any particular regimen and applies to other DAAs that currently are used or will be approved in the near future. Finally, our study incorporated the differences between regions in terms of transplant rates and provided the cost effectiveness of pre-LT HCV treatment by each UNOS region.
Our study had a number of limitations. First, our analysis did not include cirrhotic patients with hepatocellular carcinoma who receive disease exception points. Second, we did not explicitly model Child-Turcotte-Pugh class in our analysis and this should be considered in future studies as more data become available. Third, we assumed that patients could receive post-LT HCV treatment only once; however, re-treatments with oral DAAs may be offered to LT patients in the future. Fourth, we did not model patient drop-out from the waiting list resulting from MELD improvement. Although we did not consider patient delisting, recent clinical data show that only 20% patients and those with a MELD score of 20 or less were delisted because of treatment with DAAs. 24 Because our model recommended that patients with MELD scores of 23 or less receive pre-LT HCV treatment, consideration of delisting would not have changed our conclusions. However, long-term data are necessary to determine the true benefit of DAAs and their impact of delisting. Fifth, our model did not adjust for survival based on MELD score at transplant; adjusting for survival could have resulted in a higher MELD threshold to provide post-LT HCV treatment. Sixth, our model did not incorporate MELD-Sodium (Na), which was not expected to impact our results because changes in MELD-Na after SVR would be anticipated to follow the same trend as that observed with MELD. Seventh, we did not consider the fact that some patients will not tolerate ribavirin and thus would need 24 weeks of sofosbuvir and ledipasvir. Finally, our model did not account for the potential reduction in the LT waiting list size because of delisting of HCV patients after successful antiviral therapy and the decreasing need for LT in HCV patients because of the availability of DAAs.
Sensitivity analysis suggested that our model's results remained robust with an exception in patients with a MELD score of 20. The most sensitive parameter at that MELD score was the cost of LT-the lower cost of LT could make pre-LT HCV treatment more cost effective. In addition, the MELD threshold below which pre-LT treatment would be cost effective/saving increased from 21 to 25 because the price of DAAs was reduced from $95,500 to $16,100. We also accounted for uncertainty in model parameters by conducting a probabilistic sensitivity analysis and presented the probability of cost effectiveness of pre-LT treatment. We found that our results and conclusions remain robust when simultaneously accounting for uncertainty in model parameters. We also observed small differences in the cost effectiveness of HCV treatment timing by UNOS regions. Because LT rates vary across regions, patient-level decisions for cost effectiveness of pre-vs post-LT treatment should be dependent on UNOS region.
We do not recommend that clinicians or payers should make a decision about the timing of HCV treatment guided exclusively by cost-effectiveness analysis. Instead, we propose a comprehensive approach to the decision that includes patient perspective, clinical effectiveness, budget constraints, and medical urgency not captured by MELD score. For example, some patients could benefit from pre-LT HCV treatment (ie, long-term survival will be higher) compared with waiting until after the LT, even if pre-LT HCV treatment is not cost effective. In such cases, lower prices of DAAs could make pre-LT treatment cost effective.
In conclusion, our study evaluated the cost effectiveness of providing HCV treatment before and after LT in decompensated cirrhotic patients. Pre-LT HCV treatment was cost effective/saving in patients with a MELD score of 21 or less, and could be cost effective in patients with MELD scores between 22 and 25 at lower DAA prices. Post-LT treatment was the most cost-effective/ saving strategy in patients with a higher MELD score. These data should be useful in informing decision making for patients with HCV infection who are awaiting LT. 2. Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly Figure 5 . Probability of cost effectiveness of pre-LT treatment at the willingness-to-pay threshold of $100,000 per QALY.
Supplementary Material
Section S1: Transplant Rate and Mortality by United Network for Organ Sharing Region
We used UNOS-reported transplantation and death rates for each region to adjust the probability of receiving an LT and the probability of death on the waiting list. In particular, we estimated the ratio of the observed transplant rate of each region and the overall rate in the United States. By using the ratio, we estimated region-specific rates as follows: region-specific-probability ¼ regionspecific-probability ¼ 1-(1-national probability) ratio .
Section S2: Cost-Effectiveness Results by United Network for Organ Sharing Regions
We conducted a subgroup analysis to evaluate the cost-effectiveness results for each of the 11 UNOS regions. In particular, we plotted the clinical and cost effectiveness of the timing of HCV treatment by patient MELD scores in each region (Supplementary Figures 2-12 ). The dotted lines on each plot show the clinical threshold below which pre-LT treatment is more effective than post-LT treatment. Different shaded regions represent the cost effectiveness of the timing of HCV treatment. Note that a strategy is cost saving when it results in more QALYs for lower costs than the comparator, and it is cost effective when it provides more QALYs for higher costs and the ICER is less than the commonly accepted willingness-to-pay threshold (ie, $100,000 per QALY).
We found that a MELD score less than 19 before LT treatment was cost effective, and a MELD score higher than 27 after LT treatment was cost effective irrespective of the UNOS region. For MELD scores between 19 and 27, the price of DAAs in the UNOS region determined the cost effectiveness of the pre-LT HCV treatment. We found that the price threshold for DAAs below which pre-LT treatment was cost effective varied between $8600 and $74,000, depending on the MELD score and the region.
We also compared net monetary benefit of treating HCV pre-LT versus post-LT for all UNOS regions. The net monetary benefit in pre-LT treatment was higher in regions with longer time on the LT waiting list, ie, region 4-5 and 9, and vice versa ( Figure 13 ). 
